Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMP321 and tumor peptides in melanoma
NCT01308294Phase 2Terminated
- Sponsor
- Lausanne University Hospital
- Start
- Jun 2010
- Primary completion
- Apr 2014
- Countries
- 1
01
Overview
A Phase 2 trial of eftilagimod alpha in melanoma, sponsored by Lausanne University Hospital. Started Jun 2010; status: terminated.
02
Drugs
eftilagimod alpha
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01308294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01308294.